Close menu




Biotech

Photo credits: pixabay.com

Commented by André Will-Laudien on July 6th, 2021 | 13:49 CEST

Defence Therapeutics, CureVac, BioNTech - Successful therapy, earn billions!

  • Biotechnology

Since we have a large number of health-threatening issues on the table, there are just as many biotech and pharma companies that have taken up the cause of researching and combating them. Many of them are publicly traded or in the early stages of venture funding. Investors are spoiled for choice; besides good analysis, they need a fair amount of intuition and luck to find the right stock that will truly become a 500-percenter. The cancer research company CEL-SCI recently disappointed, as did the COVID vaccine expert CureVac - both shares ended in a price disaster. The question remains - which horses are the right ones?

Read

Commented by Nico Popp on July 6th, 2021 | 11:34 CEST

Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave

  • Biotechnology

Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.

Read

Commented by Carsten Mainitz on June 30th, 2021 | 12:59 CEST

CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!

  • Biotechnology

Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?

Read

Commented by Nico Popp on June 28th, 2021 | 11:15 CEST

Pfizer, Sartorius, Defence Therapeutics: Health as an investment opportunity

  • Biotechnology

Tremendous opportunities lie dormant in biotech companies. New therapeutic approaches are suitable for fighting civilization diseases such as cardiovascular problems, cancer and Alzheimer's. In recent years, there has been a whole series of scientific breakthroughs. Some studies have shown phenomenal possibilities. It is now up to innovative companies to turn laboratory findings into practical clinical results. For shareholders, the opportunities are plentiful.

Read

Commented by Stefan Feulner on June 25th, 2021 | 12:36 CEST

Nordex, XPhyto Therapeutics, Siemens AG - Growth without end

  • Biotechnology

The Federal Reserve paves the way. After discussions around possible early interest rate hikes flared up last week on the occasion of the Federal Reserve's Open Market Committee, FED head Jerome Powell came forward in person yesterday and dampened burgeoning inflation concerns. While the effects of the pickup in economic activity at the end of the Corona pandemic were stronger than forecast, they should fade over time. Therefore, the loose monetary policy will continue to drive growth - a breeding ground for development and technology stocks and further rising prices.

Read

Commented by Stefan Feulner on June 24th, 2021 | 12:52 CEST

CureVac, Cardiol Therapeutics, Bayer - Where we go from here

  • Biotechnology

Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.

Read

Commented by Carsten Mainitz on June 22nd, 2021 | 12:36 CEST

MorphoSys, Defence Therapeutics, Formycon - Biotechnology shares with great potential

  • Biotechnology

In the wake of the corona pandemic, companies such as BioNTech, Pfizer and Moderna demonstrated how quickly and safely vaccines can be developed and mass-produced using innovative biotechnological processes. Biotech stocks have risen in favor again, even outside Covid-19. However, some stocks lag behind the price targets forecast by experts, while others are slowly moving (again) in the right direction. We look at three stocks that offer excellent opportunities at the current price level.

Read

Commented by André Will-Laudien on June 18th, 2021 | 12:49 CEST

CureVac, BioNTech, Novavax, XPhyto Therapeutics - The Covid giants and the sellout!

  • Biotechnology

How quickly the tide can turn in the environment of the Corona pandemic can be seen in the vaccine manufacturers and test providers. BioNTech's share price has been rising steadily since the start of the vaccination campaign in Germany, and minor reports of potential side effects are hardly disturbing. In the case of test provider NanoRepro, the bull market of recent months is turning into a total sell-off, with the share losing over 70%. And then there is the Tübingen-based biotech Company CureVac. Delays in approval and a shock on efficacy send the share down by a whole 50% in one day. We take a closer look at the situation.

Read

Commented by Nico Popp on June 15th, 2021 | 13:15 CEST

CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio

  • Biotechnology

Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.

Read

Commented by Stefan Feulner on June 7th, 2021 | 09:37 CEST

Bayer, Defence Therapeutics, MorphoSys - A paradigm shift in biotechnology

  • Biotechnology

The search for a vaccine against the Coronavirus brought biotechnology back into the focus of investors last year. Companies such as BioNTech or CureVac were able to multiply in this regard. In 2020, the biotech sector in Germany raised a record sum of EUR 3 billion, and the trend is rising sharply. The fight against incurable diseases and the development of important innovations such as vaccines, cancer therapies, or sustainable products lift the segment into higher realms and offer attractive investment opportunities.

Read